Method for detecting genotoxic impurities in esdoxaban tosylate

Through high performance liquid chromatography and gradient elution technology, the problem of the inability to accurately detect N-oxide impurities in toluenesulfonic acid in the existing technology is solved, and the quantitative analysis of ADSB-5 impurities is achieved, ensuring that The control of drug quality, high sensitivity of the method, is suitable for common liquid chromatographs.

CN118961910APending Publication Date: 2024-11-15ZHEJIANG GUOBANG PHARMA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410863883.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing detection methods cannot accurately detect N-oxide impurities in erodoxaban toluenesulfonic acid, resulting in insufficient detection sensitivity in drugs and ineffective control of drug quality.

Method used

Using high performance liquid chromatography, phenyl-phenylapropyl silane chromatography column and UV detector, the chromatographic parameters are achieved through gradient elution and optimization of chromatographic parameters. analyze.

Benefits of technology

The accurate detection of impurities above 0.83ppm in erodoxaban p-toluenesulfonic acid is achieved, ensuring the control of drug quality. The method is simple, sensitive, accurate and reliable, and has good reproducibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961910A_ABST
    Figure CN118961910A_ABST
Patent Text Reader

Abstract

The invention provides a method for detecting genotoxic impurities in esdoxaban tosylate, and belongs to the technical field of preparation analysis and detection. According to the method, a chromatographic column with phenyl-phenylpropyl silane as a filler is used, an ammonium acetate solution-organic phase is used as a mobile phase for gradient elution, and the content of genotoxic impurities is quantitatively detected, so that the quality of the esdoxaban tosylate is effectively controlled. The detection method can be used for quantitatively detecting impurities higher than 0.83 ppm in the esdoxaban tosylate, and has the advantages of simplicity, sensitivity, accuracy, reliability, good reproducibility and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to a method for detecting genotoxic impurities in edoxaban tosylate, and belongs to the technical field of preparation analysis and detection. Background Art

[0002] Edoxaban Tosilate Hydrate, English name Edoxaban Tosilate Hydrate, molecular formula is C 31 H 40 O8ClN7S2, with a molecular weight of 738.27 and a CAS number of 1229194-11-9, is a coagulation factor Xa inhibitor indicated for reducing the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

[0003] ADSB-5 is an N-oxidized aromatic compound, a degradation impurity of edoxaban and also a genotoxic impurity. Its CAS number is 2803372-49-6 and its chemical name is: 5-chloro-2-[(2-{[(1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolyl[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl]amino}-1,2-dioxyethyl)amino]pyridine-1-oxide.

[0004]

[0005] According to the article "Warning Structure of Genotoxic Impurities" published by drug review expert Ma Lei (China New Drug Journal, Vol. 23, No. 48, 2014, 2016-2111), N-oxidized aromatic compounds are genotoxic carcinogenic impurities that need to be strictly controlled in raw materials. Therefore, it is necessary to establish accurate quantitative methods and set safe control limits.

[0006] The maximum daily intake of edoxaban tosylate is 80.8 mg. According to ICH M7 (R1), when calculating the acceptable intake of genotoxic impurities (ADSB-5) based on TTC, the risk of a single mutagenic impurity is considered to be negligible when the total acceptable daily intake is 1.5 μg / day (the theoretical cancer risk under lifetime exposure is less than one in 100,000), and the limit of ADSB-5 is 18 ppm.

[0007] CN112831843A reports a method for simultaneously detecting five genotoxic impurities in edoxaban. The five impurities targeted by the method do not include the N-oxide impurity of edoxaban. The method has a poor baseline and no accurate measurement data for the sensitivity of the method, and is not suitable for the detection of N-oxide impurities (ADSB-5) in edoxaban. Summary of the invention

[0008] In view of this, the present application provides a method for detecting genotoxic impurities in edoxaban tosylate, which can quantitatively detect impurities higher than 0.83 ppm in edoxaban tosylate, thereby effectively controlling the quality of edoxaban tosylate. The method is simple, sensitive, accurate, reliable and has good reproducibility.

[0009] Specifically, the present application is implemented through the following scheme:

[0010] A method for detecting genotoxic impurities in edoxaban tosylate, comprising: adopting high performance liquid chromatography, using a phenyl-phenylpropylsilane chromatographic column for separation, and using a UV detector for quantitative analysis, wherein the chromatographic conditions are as follows: mobile phase A is an ammonium acetate solution, mobile phase B is a mixture of mobile phase A and acetonitrile, gradient elution is performed, and the flow rate is 0.5-0.7 mL / min; the column temperature is 38-42° C.; the detection wavelength is 250 nm, and the solvent is a mixture of DMSO, acetonitrile and water.

[0011] The gradient program for gradient elution was:

[0012] Time, min 0 20 30 32 37 37.1 45 Mobile phase B, % 10 30 30 80 80 10 10 .

[0013] Further, as a preference:

[0014] The mixed volume ratio of DMSO, acetonitrile and water is 2:9:9.

[0015] Mobile phase A was an ammonium acetate solution with a pH of 4.0 and a concentration of 1.54 g / L; mobile phase B was a mixture of mobile phase A and acetonitrile in a volume ratio of 2:8.

[0016] The flow rate was 0.6 mL / min.

[0017] The column temperature was 35°C.

[0018] The specifications of the phenyl-phenylpropylsilane chromatographic column are: length 250 mm, inner diameter 4.6 mm, and filler particle size 5 μm.

[0019] The above-mentioned genotoxic impurities are those that may be generated by the degradation of edoxaban tosylate under conditions such as high temperature and the presence of oxidants, and have the structural formula:

[0020] Compared with the prior art, the advantages of the present invention are:

[0021] 1. The present invention solves the technical gap in the detection of N-oxide in edoxaban. The impurity is an oxidized impurity of edoxaban and a potential degradation impurity of the drug. It can be used as a conventional method for daily quality control of edoxaban.

[0022] 2. The present invention can perform relevant tests by using the most common liquid chromatograph in an analytical laboratory. The reagents and chromatographic columns used are simple and easy to obtain, and there is no need to use expensive technologies such as liquid-mass chromatography.

[0023] 3. The present invention achieves good separation of ADSB-5 impurities and adjacent unknown impurities by optimizing chromatographic parameters, the method has good specificity, and the sensitivity meets the requirements. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is the HPLC detection spectrum of the system suitability solution of Example 1;

[0025] Figure 2 It is the detection limit solution HPLC detection spectrum of Example 1;

[0026] Figure 3 It is the quantitative limit solution HPLC detection spectrum of Example 1;

[0027] Figure 4 It is the HPLC detection spectrum of the system suitability solution of Example 2;

[0028] Figure 5 It is the HPLC detection spectrum of the system suitability solution of Example 3;

[0029] Figure 6 It is the HPLC detection spectrum of the system suitability solution of Example 4;

[0030] Figure 7 It is the HPLC detection spectrum of the system suitability solution of Example 5;

[0031] Figure 8 It is the HPLC detection spectrum of the system suitability solution of Example 6;

[0032] Fig. 9 This is the HPLC detection spectrum of the system suitability solution of Example 7. DETAILED DESCRIPTION

[0033] The present invention is further described below in conjunction with specific examples, but is not limited to the scope of this embodiment. In the following examples, various processes and methods not described in detail are conventional methods known in the art, and the reagents used without indicating the source and specifications are all commercially available analytical or chromatographically pure.

[0034] Example 1

[0035] Instruments: High performance liquid chromatography, Agilent 1260; electronic balance, Mettler XSR105; pH meter, Mettler FE28.

[0036] Reagents: ammonium acetate (analytical grade), Sinopharm Group; acetic acid (analytical grade), Sinopharm Group; acetonitrile (chromatographic grade), iMagilab; DMSO (chromatographic grade), Scharlau.

[0037] Chromatographic conditions: Kromasil 100-5-phenyl (4.6 mm × 250 mm, 5 μm); flow rate 0.6 ml / min; detection wavelength 250 nm; injection volume 10 μL; column temperature 40 °C.

[0038] Mobile phase A was 1.54 g / L ammonium acetate aqueous solution (pH adjusted to 4.0 with acetic acid); mobile phase B was mobile phase A: acetonitrile (2:8); and the solvent was DMSO: acetonitrile: water = 2:9:9.

[0039] Elution was performed according to the following gradient program:

[0040] Time(min) 0 20 30 32 37 37.1 45 Mobile phase B (%) 10 30 30 80 80 10 10

[0041] Experimental steps:

[0042] Impurity stock solution: Weigh 12 mg of impurity ADSB-5 into a 100 ml volumetric flask, add solvent to dissolve and dilute to scale, shake well. Accurately transfer 4.5 ml of the above solution to a 100 ml volumetric flask, add solvent to dilute to scale, shake well, and obtain the impurity stock solution. (Concentration is 5.4 μg / ml)

[0043] Reference solution: Pipette 2.0 ml of impurity stock solution into a 10 ml volumetric flask, add solvent to dilute to the mark, shake well, and use as reference solution (concentration is 1.08 μg / ml)

[0044] System suitability solution: Accurately weigh 600 mg of edoxaban tosylate and place it in a 10 ml volumetric flask. Transfer 2 ml of the impurity stock solution to a volumetric flask, add solvent and ultrasonically dissolve to dilute to the scale. Shake well to prepare the system suitability solution.

[0045] Test solution: Accurately weigh 600 mg of edoxaban tosylate and place in a 10 ml volumetric flask. Add solvent and ultrasonically dissolve to the mark. Shake well to prepare the test solution.

[0046] Take the solvent, reference solution, test solution, and system suitability solution for injection, and record the ADSB-5 retention time, separation degree, and theoretical plate number. The results are shown in Table 1 and Figure 1 .

[0047] Table 1: Retention time, resolution and theoretical plate number of ADSB-5 in specificity experiments

[0048] name Retention time (ADSB-5) (min) Separation degree from adjacent peaks Theoretical plates Reference solution 26.19 / 113372 System Suitability Solutions 26.15 1.76 125398

[0049] from Figure 1 As can be seen from Table 1, ADSB-5 and adjacent impurity peaks can be completely separated, impurities can be effectively controlled, and the method system has good applicability.

[0050] 2. Detection limit and quantification limit

[0051] The detection limit of the method was 3:1, and the quantification limit of the method was 10:1. The quantification limit of ADSB-5 was 0.0536 μg / ml, and the signal-to-noise ratio was 12.03; the detection limit of impurity ADSB-5 was 0.0187 μg / ml, and the signal-to-noise ratio was 4.12. Figure 2 and Figure 3 .

[0052] 2. Linear investigation

[0053] In order to accurately determine this product and its impurities, a linear investigation was conducted, that is, the relationship between the peak area and concentration of each substance within a certain range was designed. Each linear concentration was tested starting from the quantitative limit concentration, as follows: Take an appropriate amount of ADSB-5 reference substance and weigh it accurately.

[0054] Add solvent to dissolve and dilute to prepare a series of concentrations of each reference solution, and measure according to the above method. Record the chromatogram and draw a linear regression curve with the concentration of each reference solution as the horizontal axis x and the peak area as the vertical axis y. The results are shown in Table 2.

[0055] Table 2: ADSB-5 linear equation

[0056] Impurity Name Linear equations <![CDATA[Regression coefficient R 2 > Concentration range (μg / ml) ADSB-5 y=28.248x-0.6083 0.9979 0.0536~1.2852

[0057] The test results show that within the concentration range of this product and each impurity, there is a good linear relationship between concentration and peak area.

[0058] 3. Accuracy test

[0059] Control stock solution: Weigh 12 mg of impurity ADSB-5 into a 100 ml volumetric flask, add solvent to dissolve and dilute to scale, shake well. Accurately pipette 4.5 ml of the above solution into a 100 ml volumetric flask, add solvent to dilute to scale, shake well, and obtain the impurity stock solution. (Concentration is 5.4 μg / ml)

[0060] Reference solution: Pipette 2.0 ml of reference stock solution into a 10 ml volumetric flask, add solvent to dissolve and dilute to scale, shake well. (1.08 μg / ml)

[0061] Test solution: Accurately weigh 590.88 mg of the product, place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale by ultrasonic, shake well, and use it as the test solution.

[0062] Recovery solution: Accurately weigh 600 mg of edoxaban tosylate and place it in a 10 ml volumetric flask. Pipette some of the control stock solution into the same 10 ml volumetric flask and dilute to the scale with solvent to prepare quantitative limit recovery solution (ADSB-5 content 0.0495 μg / ml), 80% recovery solution (ADSB-5 content 0.7922 μg / ml), 100% recovery solution (ADSB-5 content 0.9902 μg / ml), and 120% recovery solution (ADSB-5 content 1.1882 μg / ml).

[0063] Accurately measure 10 μl of each of the above solutions and inject them into the liquid chromatograph to record the chromatogram. Calculate the recovery rate of ADSB-5, see Table 3.

[0064] Table 3: Accuracy test results

[0065]

[0066] From Table 3, we know that the recovery of ADSB-5 in the LOQ-120% recovery solution is between 80% and 120%, and the RSD of the recovery is less than 10%, which meets the requirements and has good accuracy.

[0067] 4. Precision test

[0068] Control stock solution: Weigh 12 mg of impurity ADSB-5 into a 100 ml volumetric flask, add solvent to dissolve and dilute to scale, shake well. Accurately pipette 4.5 ml of the above solution into a 100 ml volumetric flask, add solvent to dilute to scale, shake well, and obtain the impurity stock solution. (Concentration is 5.4 μg / ml)

[0069] System suitability solution: Accurately weigh 600 mg of this product and place it in a 10 ml volumetric flask. Transfer 2 ml of the control stock solution to a volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and use this as the system suitability solution.

[0070] Reference solution: Pipette 2.0 ml of reference stock solution into a 10 ml volumetric flask, add solvent to dissolve and dilute to scale, shake well. (1.08 μg / ml)

[0071] Test solution: Accurately weigh 600 mg of the product, place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and use it as the test solution.

[0072] Test sample spike solution: weigh 600 mg of the test sample and place it in a 10 ml volumetric flask. Accurately pipette 2.0 ml of the reference sample stock solution into the same 10 ml volumetric flask, dissolve it with solvent and dilute to the mark, shake well and filter. Prepare 6 portions in the same way.

[0073] Accurately measure 10 μl of each of the above solutions and inject them into the liquid chromatograph to record the chromatogram. The intermediate precision is tested by different personnel on different dates using different instruments. The RSD value of the peak area of ​​the reference solution ADSB-5 is required not to exceed 10.0%, and the impurity recovery rate in the test solution is RSD (n=6) ≤ 10%, RSD (n=12) ≤ 10%. The test results are shown in Table 4.

[0074] Table 4: Repeatability and intermediate precision test results

[0075]

[0076] It can be seen from Table 4 that the RSD of the recovery rate of ADSB-5 in the test sample spiked solution was less than 10%, which met the requirements and had good precision.

[0077] 4. Solution stability test

[0078] After the control solution, test solution, and system suitability solution were placed at room temperature for 0 h, 3 h, 6 h, 9 h, 12 h, 30 h, and 3 d, 10 μl was accurately measured and injected into the liquid chromatograph to record the chromatogram. The test results are shown in Table 5.

[0079] Table 5: Solution stability results

[0080]

[0081] It can be seen from Table 5 that under room temperature conditions, the peak area RSD of the control solution, the test solution, and the system suitability solution were all less than 10% within 3 days. The experimental results show that the above solutions are all stable within 3 days.

[0082] Example 2

[0083] The configuration of this embodiment is the same as that of embodiment 1, except that the flow rate is 0.5 ml / min.

[0084] Take 10 μL of the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram.

[0085] The test results of the spiked solution of the test sample are shown in Table 6, and the obtained HPLC spectrum is shown in Figure 4 It can be seen that the ADSB-5 peak was effectively separated with a recovery rate of 80% to 120%.

[0086] Table 6: System suitability solution test results

[0087]

[0088] Example 3

[0089] The configuration of this embodiment is the same as that of embodiment 1, except that the flow rate is 0.7 ml / min.

[0090] Take 10 μL of the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram.

[0091] The results of the system suitability solution test are shown in Table 7, and the obtained HPLC spectrum is shown in Figure 5 It can be seen that the ADSB-5 peak was effectively separated with a recovery rate of 80% to 120%.

[0092] Table 7: System suitability solution test results

[0093]

[0094] Example 4

[0095] The configuration of this embodiment is the same as that of embodiment 1, except that the column temperature is 38°C.

[0096] Take 10 μL of the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram.

[0097] The results of the system suitability solution test are shown in Table 8, and the obtained HPLC spectrum is shown in Figure 6 It can be seen that the ADSB-5 peak was effectively separated with a recovery rate of 80% to 120%.

[0098] Table 8: System suitability solution test results

[0099]

[0100] Example 5

[0101] The configuration of this embodiment is the same as that of embodiment 1, except that the column temperature is 42°C.

[0102] Take 10 μL of the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram.

[0103] The results of the system suitability solution test are shown in Table 9, and the obtained HPLC spectrum is shown in Figure 7 It can be seen that the ADSB-5 peak was effectively separated with a recovery rate of 80% to 120%.

[0104] Table 9: System suitability solution test results

[0105]

[0106] Example 6

[0107] The configuration of this embodiment is the same as that of embodiment 1, except that the mobile phase A is adjusted to pH 3.9 with phosphoric acid.

[0108] Take 10 μL of the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram. The system suitability solution test results are shown in Table 10, and the obtained HPLC spectrum is shown in Figure 8 It can be seen that the ADSB-5 peak was effectively separated and the recovery rate was between 80% and 120%.

[0109] Table 10: System suitability solution test results

[0110]

[0111] Example 7

[0112] The configuration of this embodiment is the same as that of embodiment 1, except that the mobile phase A is adjusted to pH 4.1 with phosphoric acid.

[0113] Take 10 μL of the system suitability solution, inject it into the liquid chromatograph, and record the chromatogram. The system suitability solution test results are shown in Table 11, and the obtained HPLC spectrum is shown in Fig. 9 It can be seen that the ADSB-5 peak was effectively separated with a recovery rate of 80% to 120%.

[0114] Table 11: System suitability solution test results

[0115]

Claims

1. A method for detecting genotoxic impurities in edoxaban tosylate, characterized in that: The method adopts high performance liquid chromatography, uses a phenyl-phenylpropylsilane chromatographic column for separation, and uses a UV detector for quantitative analysis. The chromatographic conditions are as follows: mobile phase A is an ammonium acetate solution, and mobile phase B is a mixture of mobile phase A and acetonitrile, and gradient elution is performed at a flow rate of 0.5 to 0.7 mL / min; the column temperature is 38 to 42° C.; the detection wavelength is 250 nm, and the solvent is a mixture of DMSO, acetonitrile, and water. The gradient program for gradient elution was: 。 2. A method for detecting genotoxic impurities in edoxaban tosylate according to claim 1, characterized in that: The mixed volume ratio of DMSO, acetonitrile and water is 2:9:

9.

3. A method for detecting genotoxic impurities in edoxaban tosylate according to claim 1, characterized in that: Mobile phase A was an ammonium acetate solution with a pH of 4.0 and a concentration of 1.54 g / L; mobile phase B was a mixture of mobile phase A and acetonitrile in a volume ratio of 2:

8.

4. The method for detecting genotoxic impurities in edoxaban tosylate according to claim 1, characterized in that: The flow rate was 0.6 mL / min.

5. The method for detecting genotoxic impurities in edoxaban tosylate according to claim 1, characterized in that: The column temperature was 35°C.

6. The method for detecting genotoxic impurities in edoxaban tosylate according to claim 1, characterized in that: The specifications of the phenyl-phenylpropylsilane chromatographic column are: length 250 mm, inner diameter 4.6 mm, and filler particle size 5 μm.

7. A method for detecting genotoxic impurities in edoxaban tosylate according to any one of claims 1 to 6, characterized in that: The structural formula of the genotoxic impurity is: